Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Next revisionBoth sides next revision
home:diseases:co-infections [06.07.2011] paulalberthome:diseases:co-infections [06.08.2011] – [Types] paulalbert
Line 8: Line 8:
 Because the Marshall Protocol activates the innate immune response, a system that is responsive to a range of microbes, there is a good chance the MP targets these infections. Patients on the MP experience an immunopathological reaction in eliminating any microbes including those labelled as co-infections. Because the Marshall Protocol activates the innate immune response, a system that is responsive to a range of microbes, there is a good chance the MP targets these infections. Patients on the MP experience an immunopathological reaction in eliminating any microbes including those labelled as co-infections.
  
 +===== Types =====
  
 +  * //**Bartonella**// – A genus of Gram-negative bacteria. Facultative intracellular parasites, //Bartonella// species can infect healthy people but are considered especially important as opportunistic pathogens.
 +  * //**Borellia**//
 +  * //Babesia// – //Babesia// is a protozoan parasite of the blood that causes a hemolytic disease known as Babesiosis. There are over 100 species of //Babesia// identified.
 +  * //**Candida albicans**// – //Candida// is a fungus (a form of yeast) that plays a role in opportunistic oral and genital infections in humans. //C. albicans// biofilms readily form on the surface of implantable medical devices. Systemic fungal infections (fungemias) have emerged as important causes of morbidity and mortality in patients traditionally labelled as immunocompromised, e.g., AIDS, cancer chemotherapy, organ or bone marrow transplantation. According to the Marshall Pathogenesis, patients suffering from chronic diseases are also immunocompromised. //See article [[home:othertreatments:antifungals|antifungal agents]]//.
 +  * **cytomegalovirus**
 +  * //**Ehrlicha**//
 +  * **Epstein-Barr virus**
 +  * //**Rickettsia**//
 ===== Term can be ambiguous ===== ===== Term can be ambiguous =====
  
Line 18: Line 27:
  
  
-===== Marshall Protocol targets co-infections =====+===== Marshall Protocol targets "co-infections=====
  
 <relatedarticle> [[home:pathogenesis:innate_immunity|Innate immune response and Th1 inflammation]]  </article> <relatedarticle> [[home:pathogenesis:innate_immunity|Innate immune response and Th1 inflammation]]  </article>
  
-Using the VDR agonist, olmesartan, the MP activates the innate immune response. The innate immune response is effective against a range of microbes – including and especially co-infections. One component of the innate immune response is the antimicrobial peptides.+Using the VDR agonist, olmesartan, the MP activates the innate immune response. The innate immune response is effective against a range of microbes including "co-infections.One important component of the innate immune response is the antimicrobial peptides. 
  
 {{section>:home:pathogenesis:innate_immunity#antimicrobial_peptides_target_fungi_and_viruses&noheader}} {{section>:home:pathogenesis:innate_immunity#antimicrobial_peptides_target_fungi_and_viruses&noheader}}
home/diseases/co-infections.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.